Baidu
map

LANCET:甲氨蝶呤能否增加关节内皮质类固醇对幼年关节炎的疗效?

2017-02-07 MedSci MedSci原创

\目前,很少有基于证据的信息可用于指导治疗低聚幼年特发性关节炎。近期,一项发表在权威杂志LANCET上的文章研究了口服甲氨蝶呤能否增加关节内皮质类固醇的疗效。这是一项在意大利十家医院进行的前瞻性、开放性、随机试验。将18岁以下的患病儿童随机分配(1:1)分为单独关节内予以皮质类固醇或与口服甲氨蝶呤组合(15mg / m 2;最大20mg)两组。使用的皮质类固醇是曲安奈德(肩、肘、腕、膝和胫骨关节)

\目前,很少有基于证据的信息可用于指导治疗低聚幼年特发性关节炎。近期,一项发表在权威杂志LANCET上的文章研究了口服甲氨蝶呤能否增加关节内皮质类固醇的疗效。


这是一项在意大利十家医院进行的前瞻性、开放性、随机试验。将18岁以下的患病儿童随机分配(1:1)分为单独关节内予以皮质类固醇或与口服甲氨蝶呤组合(15mg / m 2;最大20mg)两组。使用的皮质类固醇是曲安奈德(肩、肘、腕、膝和胫骨关节)或醋酸甲泼尼龙(如距下和跗骨关节)。此项研究没有掩盖患者或研究者治疗分配的信息。研究的主要结果是意向治疗人群中在12个月时所有注射关节中关节炎缓解的患者比例。该试验在欧盟临床试验注册登记,EudraCT号2008-006741-70。

研究结果显示:2009年7月7日至2013年3月31日,共筛选226名参与者,随机分配102名患者进行单独的关节内皮质类固醇治疗;105名患者进行关节内皮质类固醇加甲氨蝶呤治疗。单独使用关节内皮质类固醇治疗组中有33例(32%)患者,关节内皮质类固醇和甲氨蝶呤联合治疗组有39例(37%)患者所有注射关节的关节炎得到缓解(p = 0.48)。接受甲氨蝶呤联合治疗组中有20名(17%)患者出现不良事件,其中有两名患者永久治疗停止(一名由于肝转氨酶增加,一名由于胃肠道不适)。没有患者发生严重不良事件。

此项研究得出结论:联合予以甲氨蝶呤没有增加关节内皮质类固醇治疗的有效性。需要进一步的研究来确定最佳治疗策略。

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1828764, encodeId=8f271828e64d4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 23 22:38:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265374, encodeId=427212653e48f, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Feb 09 11:38:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313362, encodeId=358913133623f, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Feb 09 11:38:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174905, encodeId=491d1e4905c4, content=学习了,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbdb2008644, createdName=Arbbin, createdTime=Wed Feb 08 08:49:21 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174900, encodeId=d1021e49006a, content=学习了,非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Wed Feb 08 08:24:21 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174856, encodeId=18fc1e48566a, content=长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Wed Feb 08 05:53:52 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
    2017-09-23 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1828764, encodeId=8f271828e64d4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 23 22:38:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265374, encodeId=427212653e48f, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Feb 09 11:38:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313362, encodeId=358913133623f, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Feb 09 11:38:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174905, encodeId=491d1e4905c4, content=学习了,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbdb2008644, createdName=Arbbin, createdTime=Wed Feb 08 08:49:21 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174900, encodeId=d1021e49006a, content=学习了,非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Wed Feb 08 08:24:21 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174856, encodeId=18fc1e48566a, content=长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Wed Feb 08 05:53:52 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
    2017-02-09 lmm397
  3. [GetPortalCommentsPageByObjectIdResponse(id=1828764, encodeId=8f271828e64d4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 23 22:38:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265374, encodeId=427212653e48f, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Feb 09 11:38:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313362, encodeId=358913133623f, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Feb 09 11:38:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174905, encodeId=491d1e4905c4, content=学习了,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbdb2008644, createdName=Arbbin, createdTime=Wed Feb 08 08:49:21 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174900, encodeId=d1021e49006a, content=学习了,非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Wed Feb 08 08:24:21 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174856, encodeId=18fc1e48566a, content=长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Wed Feb 08 05:53:52 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1828764, encodeId=8f271828e64d4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 23 22:38:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265374, encodeId=427212653e48f, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Feb 09 11:38:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313362, encodeId=358913133623f, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Feb 09 11:38:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174905, encodeId=491d1e4905c4, content=学习了,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbdb2008644, createdName=Arbbin, createdTime=Wed Feb 08 08:49:21 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174900, encodeId=d1021e49006a, content=学习了,非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Wed Feb 08 08:24:21 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174856, encodeId=18fc1e48566a, content=长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Wed Feb 08 05:53:52 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
    2017-02-08 Arbbin

    学习了,谢谢!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1828764, encodeId=8f271828e64d4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 23 22:38:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265374, encodeId=427212653e48f, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Feb 09 11:38:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313362, encodeId=358913133623f, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Feb 09 11:38:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174905, encodeId=491d1e4905c4, content=学习了,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbdb2008644, createdName=Arbbin, createdTime=Wed Feb 08 08:49:21 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174900, encodeId=d1021e49006a, content=学习了,非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Wed Feb 08 08:24:21 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174856, encodeId=18fc1e48566a, content=长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Wed Feb 08 05:53:52 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
    2017-02-08 天涯183

    学习了,非常好

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1828764, encodeId=8f271828e64d4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 23 22:38:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265374, encodeId=427212653e48f, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Feb 09 11:38:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313362, encodeId=358913133623f, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Feb 09 11:38:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174905, encodeId=491d1e4905c4, content=学习了,谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbdb2008644, createdName=Arbbin, createdTime=Wed Feb 08 08:49:21 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174900, encodeId=d1021e49006a, content=学习了,非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Wed Feb 08 08:24:21 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174856, encodeId=18fc1e48566a, content=长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Wed Feb 08 05:53:52 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
    2017-02-08 卡圣

    长见识了

    0

相关资讯

Neurology:甲氨蝶呤用于全身型重症肌无力能否带来获益?

发表在Neurology的一项研究旨在确定有症状的全身型重症肌无力(MG)患者中甲氨蝶呤(MTX)的类固醇样效应。结果表明,经过12个月的治疗,对于全身型MG患者,MTX并没有显著降低强的松的药时曲线下面积。该研究旨在确定有症状的全身型重症肌无力(MG)患者中甲氨蝶呤(MTX)的类固醇样效应。研究人员进行了一项12个月、多中心、随机、双盲、安慰剂对照试验,该项试验于2009年4月~2014年8月在

盘点:关于甲氨蝶呤用药新近进展

甲氨蝶呤为抗叶酸类抗肿瘤药,主要通过对二氢叶酸还原酶的抑制而达到阻碍肿瘤细胞的合成,而抑制肿瘤细胞的生长与繁殖。在用甲氨蝶呤后,加用甲酰四氢叶酸钙,可直接向细胞提供四氢叶酸辅酶,避开甲氨蝶呤的抑制作用,以减轻其细胞毒的毒性作用。甲氨蝶呤(MTX),是一种既有抗炎又有抗肿瘤特性的有效叶酸拮抗剂,广泛应用于很多自身免疫性疾病,包括类风湿性关节炎(RA),银屑病,和炎症性肠病(IBD)的治疗。在过去

Lancet:皮下注射甲氨蝶呤治疗中重度斑块型银屑病的强化给药方案

该研究结果显示银屑病患者皮下注射氨甲喋呤在治疗52周可以得到可喜的风险-效益比。对待这类使用甲氨喋呤的患者时应考虑给药途径和强化给药方案。

BMJ:甲氨蝶呤 vs 甲氨蝶呤联合疾病修饰性抗风湿药物治疗类风湿性关节炎

该研究的目的是比较基于缓解疾病的抗风湿性药物(DMARD)甲氨蝶呤治疗未经治疗过的类风湿性关节炎患者或对甲氨蝶呤反应不足的患者治疗结果。原始出处:Glen S Hazlewood,Cheryl Barnabe,George Tomlinson,et al.Methotrexate monotherapy and methotrexate combination therapy with tradi

J Clin Oncol:高危B-ALL患者来说,接受大剂量甲氨蝶呤治疗可更好地改善其生存率

儿童和年轻成人高危B-急性淋巴细胞白血病(B-ALL)的预后已明显改善,但是仍有20-25%的患者并不能治愈。儿童肿瘤学小组AALL0232测试了两项干预措施以提高患者的生存率。 2004年1月至2011年1月研究人员共纳入了3154名新诊断为高危B-ALL的患者,年龄为1-30岁。采用2 × 2析因设计,将2914名患者随机分至诱导期接受地塞米松(14天)VS.泼尼松(28天)治疗,中间维

Eur J Gas & Hep:甲氨蝶呤治疗克罗恩病的可行性

MTX治疗克罗恩病,至少有1/3的患者可以达到无类固醇依赖的临床缓解,有将近2/3的治疗有反应患者无复发生存期达到1年。MTX应被视为克罗恩病患者其他疗法无效时的可行的治疗选择。

Baidu
map
Baidu
map
Baidu
map